Free tool
FAERS Monitor: Tyenne
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761449 or its brand name (Tyenne, Tocilizumab-Aazg). Reports on generic versions are filed under their own applications.
Reports
616
Serious
358
58% of reports
Hospitalization
160
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective42
- headache41
- arthralgia40
- pain39
- pruritus38
- urticaria36
- rheumatoid arthritis31
- rash28
- fatigue27
- death25
- product substitution issue23
- anaphylactic reaction22
- off label use20
- peripheral swelling19
- diarrhoea18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 53 |
| 2025 | 186 |
| 2026 | 369 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,543 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 23 | 13.6 | 9.1 | 258 |
| anaphylactic reactionSignal | 22 | 13.6 | 9.0 | 245 |
| rheumatoid arthritisSignal | 31 | 9.3 | 6.6 | 223 |
| urticariaSignal | 36 | 7.3 | 5.3 | 192 |
| peripheral swellingSignal | 19 | 4.2 | 2.7 | 44 |
| pruritusSignal | 38 | 3.4 | 2.5 | 62 |
| arthralgiaSignal | 40 | 3.3 | 2.4 | 63 |
| headacheSignal | 41 | 2.2 | 1.7 | 28 |
| rashSignal | 28 | 2.2 | 1.5 | 17 |
| painSignal | 39 | 2.2 | 1.6 | 24 |
| fatigue | 27 | 1.2 | 0.8 | 1 |
| drug ineffective | 42 | 1.1 | 0.8 | 0 |
| death | 25 | 1.0 | 0.7 | 0 |
| diarrhoea | 18 | 1.0 | 0.6 | 0 |
| off label use | 20 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.